Articles by tag: asco-2026

Immunotherapy for endometrial cancer: ASCO 2026 data

Analysis of the NRG-GY018 study: pembrolizumab + chemotherapy improved survival in endometrial cancer. Risk of death reduced by 44% in dMMR. Details at ASCO 2026.

Breakthrough in glioblastoma treatment: NeoVax vaccine improves survival | ASCO 2026

Dana-Farber's personalized vaccine NeoVax showed median survival of 36.9 months in glioblastoma at ASCO 2026. Learn how immunotherapy works and who it suits.

ASCO 2026: biomarkers of response to Reqorsa gene therapy for lung cancer

Reqorsa gene therapy identified TROP2 and PTEN biomarkers for lung cancer prognosis. Learn ASCO 2026 data and prospects for treating NSCLC and SCLC.

Gedatolisib: Phase 3 success in PIK3CA-mutated cancer

Gedatolisib met the endpoint in the VIKTORIA-1 study, surpassing the standard of care. Learn how this will change the market. Read the detailed analysis.